ArticleCanadian respiratory journal2018
Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients.
Article in Canadian respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Clinical aspects encountered in patients with portopulmonary hypertension.Medicine and pharmacy reports · 2025Review
- Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography.Scientific reports · 2025Article
- Article
- Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1.Kidney international reports · 2025Article
- [Pulmonary Complications in Patients with Liver Cirrhosis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Portopulmonary Hypertension: An Updated Review.Transplantation direct · 2023Review
- Current clinical understanding and effectiveness of portopulmonary hypertension treatment.Frontiers in medicine · 2023Review
- Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry.Circulation reports · 2022Article
- Cardiac risk stratification of the liver transplant candidate: A comprehensive review.World journal of transplantation · 2022Review
- Portopulmonary hypertension: Current developments and future perspectives.Liver research (Beijing, China) · 2022Review
- Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis.International journal of general medicine · 2022Article
- The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.BMC pulmonary medicine · 2021Observational
- Prevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case-Control Study.BioMed research international · 2021Article
- Pulmonary manifestations of chronic liver disease: a comprehensive review.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prevalence and prognosis of portopulmonary hypertension (PoPH) in liver transplant recipients. Methods: Patients with advanced liver disease who underwent orthotopic liver transplantation (OLT) were included in this retrospective study from January 2012 to June 2015. According to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis of pulmonary hypertension (PH), patients with tricuspid regurgitation velocity (TRV) >3.4 m/s or 2.9 m/s ≤ TRV ≤ 3.4 m/s coexisting with other echocardiographic PH signs were judged as PH. PH patients with portal hypertension and without other known causes of PH were diagnosed as PoPH. Results: A total of 223 (170 males and 53 females) middle-aged (50.9 ± 9 years old) liver transplant recipients were included in this study. Fourteen patients (6.3%) were diagnosed with PoPH, and none of the patients were treated with vasodilators before or after OLT. After OLT, patients were followed up for 26 ± 13.5 months. In total, 8 of 14 (57%) PoPH patients died, and the main cause of death was pulmonary infection. Kaplan-Meier survival curves revealed a significant difference in survival between PoPH and non-PoPH patients ( Conclusions: The prevalence of PoPH was 6.3% in OLT recipients. The survival of untreated PoPH patients was dismal after OLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.